PHARMAFOCUS 2028
June 2024Gerry Jeffcott, Bill Dempster, Don Sancton, Michel Parent, Jodie Kiss | IQVIA
THE CANADIAN DRUG AGENCY: THE FEDERAL GOVERNMENT’S NATIONAL PHARMACARE AGENDA GIVES CADTH A NEW NAME AND AN EXPANDED MANDATE
May-June 2024William Dempster and Trevor Richter | Value & Outcomes Spotlight (ISPOR)
PROFILES IN REIMBURSEMENT – CONTRIBUTIONS MADE BY THE BRITISH COLUMBIA PHARMACEUTICAL, LABORATORY AND BLOOD SERVICES DIVISION (BC PLBSD)
May 2024Gerry Jeffcott | Provincial Reimbursement Advisor
CANADIANS NEED ACCESS TO MEDICINES – AFTER THAT, THERE’S LITTLE AGREEMENT ON PHARMACARE PLANS
May 2024Don Sancton | Provincial Reimbursement Advisor
THE CASE OF THE MISSING FEDERAL MONEY
February 2024Gerry Jeffcott | Provincial Reimbursement Advisor
ADAPTING HEALTH TECHNOLOGY ASSESSMENT AGENCY STANDARDS FOR SURROGATE OUTCOMES IN EARLY STAGE CANCER TRIALS: WHAT NEEDS TO HAPPEN?
January 2024William Dempster (Kristian Thorlund et al.) | Expert Review of Pharmacoeconomics & Outcomes Research
OPPORTUNITIES FOR EARLIER ACCESS TO NEW MEDICINES
November 2023Philip Delistoyanov and Bill Dempster | Provincial Reimbursement Advisor
PHARMAFOCUS 2027 UPDATE
November 2023Gerry Jeffcott, Bill Dempster, Don Sancton, Michel Parent, Stephanie Levee | IQVIA
UNDER THE MICROSCOPE: EXAMINING MEDICATION SPENDING GROWTH ACROSS CANADA
August 2023Gerry Jeffcott | Provincial Reimbursement Advisor
PHARMAFOCUS 2027
June 2023Gerry Jeffcott, Bill Dempster, Don Sancton, Michel Parent, Jodie Kiss, Stephanie Levee | IQVIA